Article
Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer.
Clinical genitourinary cancer - 1 Jun 2021
Chipidza Fallon E, Alshalalfa Mohammed, Mahal Brandon A, Karnes R Jeffrey, Liu Yang, Davicioni Elai, Martin Neil E, Mouw Kent W, Feng Felix Y, Nguyen Paul L, Muralidhar Vinayak
Abstract excerpt
INTRODUCTION: Prostate tumors with TP53 gene mutations are molecularly heterogenous, and the presence of TP53 gene mutations has been linked to inferior outcomes. We developed an RNA-based gene signature that detects underlying TP53 gene mutations and identifies wild-type prostate tumors that are analogous to TP53-mutant tumors. MATERIALS AND METHODS: Using genomic expression profiles from The Cancer Genome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.